Wallace H. Coulter Foundation
790 NW 107th Avenue, Suite 215, Miami, FL, 33172-3158, United States
Overview
The Wallace H. Coulter Foundation supports scientific and medical associations to develop innovative educational programs intended to improve the quality of care in resource-limited areas. They also support Asian American Pacific Islander (AAPI) organizations, establishing one cohesive community, and promoting collaboration and partnerships.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Investment portfolio
- CSATS
Participated · Equity · Jun 2015
C-SATS provides a cloud-based performance management system that uploads operating-room video to a secure server and uses an algorithm to match recordings with procedure-specific assessment tools. The platform dispatches vetted, trained experts (including non-surgeons) who are paid to review videos and assess surgical performance, completing reviews within two to three hours. C-SATS positions this workflow as faster, less biased, and far less costly than conventional peer review, arguing it can improve surgeon skill, productivity, compliance, and help reduce costs for hospitals. The company markets a software-as-a-service model and pays reviewers per assessment; customers named in the article include Seattle Children’s Hospital, University of Toronto, University of Connecticut, Virginia Mason, Ford Health System, and Florida Hospital Nicholson Center. The startup spun out of the University of Washington, is headquartered in Seattle’s University District, and has been on the market for about nine months. Financially, C-SATS recently raised $2.5 million and has also received grant funding from the Wallace H. Coulter Foundation and the University of Washington.
- QLIDA Diagnostics
Participated · Series A · May 2012
QLIDA is developing a point-of-care mobile diagnostic device that uses a disposable pin-prick blood sample to detect cardiac biomarkers such as troponin and BNP, and was first developed to detect myeloperoxidase. The company says its test is more sensitive and cost-effective than others in development and can measure multiple biomarkers simultaneously to meet clinicians' needs. QLIDA's technology was developed by Elisabeth Papazoglou; Michael Boyce-Jacino is the company's CEO. The device is intended to improve triage, cut emergency-room wait times, and track near-term heart-attack risk. The firm plans to expand the platform to emerging biomarkers across cardiovascular disease, diabetes and cancer. QLIDA has received funding from the Coulter Foundation, Ben Franklin Partners of Southeast Pennsylvania and UK-based VC Net Scientific as it advances development.
Team
No current team members are available.